Use of a two‐sided tolerance interval in the design and evaluation of biosimilarity in clinical studies.

Summary: In assessing biosimilarity between two products, the question to ask is always "How similar is similar?" Traditionally, the equivalence of the means between products is the primary consideration in a clinical trial. This study suggests an alternative assessment for testing a certain percentage of the population of differences lying within a prespecified interval. In doing so, the accuracy and precision are assessed simultaneously by judging whether a two‐sided tolerance interval falls within a prespecified acceptance range. We further derive an asymptotic distribution of the tolerance limits to determine the sample size for achieving a targeted level of power. Our numerical study shows that the proposed two‐sided tolerance interval test controls the type I error rate and provides sufficient power. A real example is presented to illustrate our proposed approach. [ABSTRACT FROM AUTHOR]